Answers are grounded in this paper and cite their sources.
Clofazimine (CFZ) is a therapeutic option for pulmonary nontuberculous mycobacterial (NTM) infections; however, knowledge on its pharmacokinetics and drug–drug interactions remains limited. This study evaluated the pharmacokinetics and adverse events associated with concomitant administration of CFZ, clarithromycin (CAM), amikacin (AMK), and imipenem (IPM) in patients with pulmonary Mycobacterium abscessus complex (MABC) disease. Patients diagnosed with pulmonary MABC were treated with combined CFZ, CAM, AMK, and IPM. Serum drug concentrations were measured on days 1 and 13 using liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were calculated using a noncompartmental analysis model, and their relationship with adverse events (AEs) was evaluated. Ten patients participated with a mean age of 65.5 years (49–74 years). Both CFZ and CAM exhibited significant accumulation by day 13 compared with day 1, whereas AMK and IPM showed no notable pharmacokinetic changes. Patients who experienced nausea and vomiting had significantly higher CFZ trough levels, CAM area under the serum concentration–time curve to the last quantifiable concentration (AUC last ), and IPM AUC last than those without these symptoms. One case exhibited QT interval prolongation; however, no association with plasma drug concentrations was identified. CAM, which typically does not accumulate with monotherapy, showed approximately twofold accumulation when co-administered with CFZ, indicating a potential pharmacokinetic drug–drug interaction between these drugs.
No takes yet. Share an insight, caveat, or question.
Enoki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: